- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01802944
Intranasal Insulin: A Novel Treatment for Gulf War Multisymptom Illness
Following their deployment to the 1991 Gulf War, many veterans (GWV) reported a constellation of unexplained health symptoms; common among them were attention and memory difficulties, fatigue, joint pain, headaches, gastrointestinal complaints, and mood and sleep problems. Despite the passage of time, the symptom complex persists for many veterans. Indeed, it is estimated that at least 25 percent of GWV (nearly 170,000 veterans) have a persistent form of chronic multisymptom illness (CMI). GW deployed veterans are also developing significantly more chronic diseases such as diabetes, hypertension, arthritis, and coronary heart disease than their non-deployed veteran peers putting these individuals at risk for accelerated aging-related diseases of the peripheral and central nervous system (CNS). Recent studies have shown a slowing of response speed that affects mental flexibility across multiple cognitive domains (memory, attention, visuospatial functions) especially on tests that were timed and computerized and where small differences in cognitive reaction times could be measured. Recent studies also have suggested that the response inhibition deficits shown in GWV may reflect executive system dysfunction as reflected by slower motor responses across multiple cognitive domains.
To date, there are no treatments that have been shown to improve the health or cognitive difficulties of GW veterans; thus there is an urgent need to establish effective, safe, and tolerable treatments for GW CMI. Previous studies in other cognitive disorders have found that intranasal insulin improves memory, attention, and mood, reduces neuroinflammation, and modulates cortisol levels; it has also been identified as a treatment that has the capacity to alter many of the leading problems of GW CMI.
During this study there are 2 treatment groups and a placebo group that will last for 8 weeks. The treatment groups will self-administer their designated dosage of insulin through a nasal pump twice a day, while the placebo group will administer saline through a nasal pump twice a day. These doses have been shown to be effective and safe. The primary outcome measure will assess improvements in verbal delayed memory using a specific list learning task and on a measure of selective attention. The study will assess improvements in overall physical health and mood by asking the participants to complete self report questionnaires. Neuroendocrine measures will also be obtained in order to evaluate changes in glucose, insulin, and cortisol levels and examine their impact on GW CMI.
Intranasal insulin has shown great promise in improving memory, attention, and mood in both older adults with cognitive impairment as well as normal subjects. Thus, this proposal could prove intranasal insulin to be an effective, safe, and affordable therapy for these ailing veterans.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02130
- Recruiting
- VA Boston Healthcare System
-
Contact:
- Maxine Krengel, PhD
- Phone Number: 617-232-9500
- Email: Maxine.Krengel@va.gov
-
Principal Investigator:
- Maxine Krengel, PhD
-
-
New York
-
The Bronx, New York, United States, 10468
- Recruiting
- James J. Peters VA Medical Center
-
Contact:
- Julia A Golier, MD
- Phone Number: 5196 718-584-9000
- Email: Julia.Golier@va.gov
-
Principal Investigator:
- Julia A Golier, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is a veteran of the 1991 Gulf War.
- Veteran meets criteria for chronic multisymptom illness based Kansas Gulf War Study (Steele, 2000) criteria and must meet criteria in the cognitive symptom domain.
Exclusion Criteria:
- Veteran lacks the capacity to provide consent.
- Veteran has diabetes, a major medical or neurological disorder or moderate-severe traumatic brain injury.
- Veteran has a history of hypoglycemia.
- Veteran is taking oral or nasal corticosteroids, insulin or oral hypoglycemic agents.
- Veteran has an irregular nasal cavity (i.e. nasal polyps etc.) or is using nasal sprays on a regular basis.
- Veteran has a lifetime diagnosis of schizophrenia, schizoaffective disorder or type I bipolar disorder.
- Veteran is at high risk from a mental perspective as evidence by having been psychiatrically hospitalized or attempted suicide within the previous 2 years or has current active suicidal ideation.
- Veteran is pregnant or breastfeeding or plans to become pregnant within the year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 10 IU BID
10 IU BID Intranasal Insulin
|
|
Experimental: 20 IU BID
20 IU BID Intranasal Insulin
|
|
Experimental: PLACEBOS
Saline nasal solution used as placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Memory Functioning
Time Frame: Eight weeks
|
To assess the efficacy of two different doses (10 IU BID and 20 IU BID) of daily intranasal insulin for eight weeks on memory functioning in Gulf War Veterans with Chronic Multisymptom Illness.
The primary clinical outcome measure will be a change in the performance on the delayed verbal memory score on a list learning task (California Verbal Learning Test (CVLT).
To determine the sustainability of change in cognitive status, the response from treatment endpoint (end of 8-week treatment period) to one month follow-up (post end of 8-week treatment period) will also be assessed for the primary outcome measure.
|
Eight weeks
|
Attention Functioning
Time Frame: Eight Weeks
|
To assess the efficacy of two different doses (10 IU BID and 20 IU BID) of daily intranasal insulin for eight weeks on attention functioning in Gulf War Veterans with Chronic Multisymptom Illness.
The primary clinical outcome measure will be a change in performance on a selective attention task (Stroop Color-Word Interference Task) from treatment baseline to endpoint.
To determine the sustainability of change in cognitive status, the response from treatment endpoint (end of 8-week treatment period) to one month follow-up (post end of 8-week treatment period) will also be assessed for the outcome measure.
|
Eight Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical Health
Time Frame: Eight weeks
|
An outcome measure will be the changes in physical health over the course of active treatment.
The primary measure of physical health will be the Physical Components Score (PCS) from the Standard Form 12-veteran version (SF-12V).
The clinical outcome measure will be the change in PCS score from treatment baseline to endpoint.
To determine the sustainability of change in PCS scores, the response from treatment endpoint to one month follow-up will also be assessed.
|
Eight weeks
|
Mood
Time Frame: Eight Weeks
|
An outcome measure will be the changes in mood over the course of active treatment.
The primary measure of mood will be obtained from the Profile of Mood States (POMS) vigor scale.
The clinical outcome measure will be the change in POMS scores from treatment baseline to endpoint.
To determine the sustainability of change in POMS scores, the response from treatment endpoint to one month follow-up will also be assessed.
|
Eight Weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Julia Golier, MD, Chief of Psychiatry Bronx VA Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GW110054
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Multisymptom Illness in Gulf War Veterans
-
Bronx Veterans Medical Research Foundation, IncU.S. Army Medical Research and Development CommandCompletedChronic Multisymptom Illness in Gulf War VeteransUnited States
-
VA Office of Research and DevelopmentGeorgetown University; MedStar HospitalsCompleted
-
National Institute of Neurological Disorders and...RecruitingGulf War IllnessUnited States
-
East Carolina UniversityCompletedGulf War IllnessUnited States
-
K-PAX Pharmaceuticals, Inc.VA Palo Alto Health Care SystemUnknownGulf War IllnessUnited States
-
Nova Southeastern UniversityBoston University; RTI InternationalRecruiting
-
VA Office of Research and DevelopmentTexas A&M UniversityTerminatedGulf War IllnessUnited States
-
Icahn School of Medicine at Mount SinaiUnited States Department of Defense; Department of Veterans Affairs, New JerseyCompletedGulf War IllnessUnited States
-
University at AlbanyUnited States Department of Defense; Women's College Hospital; The Sage Colleges and other collaboratorsCompleted
-
Boston University Charles River CampusUnknownGulf War IllnessUnited States
Clinical Trials on Intranasal Insulin
-
Michigan State UniversityCompletedExercise | InsulinUnited States
-
Wake Forest University Health SciencesCompleted
-
University Health Network, TorontoCompleted
-
University of BirminghamQueen Elizabeth Hospital NHS Foundation TrustCompleted
-
Texas Tech University Health Sciences CenterCompletedHypogonadotropic HypogonadismUnited States
-
Johns Hopkins UniversityTerminatedHIV Dementia | HIV-Associated Cognitive Motor ComplexUnited States
-
University Health Network, TorontoCompletedInsulin Resistance, DiabetesCanada
-
Centre for Addiction and Mental HealthRecruitingDepression | Major Depressive DisorderCanada
-
HealthPartners InstituteJuvenile Diabetes Research Foundation; International Diabetes Center at Park...TerminatedType1diabetesUnited States
-
Rutgers, The State University of New JerseyAlzheimer's AssociationRecruitingMetabolic Syndrome | Alzheimer Disease | Mild Cognitive ImpairmentIsrael